Trials / Completed
CompletedNCT01439776
Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients
A Randomized, Multi-center, Phase IV Open-label Study Evaluating the Antiviral Efficacy of Addition of Vitamin D in Patients With Treatment Naïve Chronic Hepatitis C Receiving Peginterferon Alfa-2a Plus Ribavirin
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 180 (actual)
- Sponsor
- Hanyang University · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Standard therapy for chronic hepatitis C virus (HCV) is (Peg/RBV) combination therapy obtaining sustained virologic response (SVR) in 77% of naïve patients with genotype 1-3 Studies rarely address the issues of improving host factors. The current study examines whether adding vitamin D with Peg/RBV, a potent immunomodulator, could improve viral response(SVR)compared to Peg/RBV.
Detailed description
The working hypothesis is that Adding vitamin D to conventional Peg/RBV therapy for naïve, genotype 1-3 patients with chronic HCV infection significantly improves RVR, EVR additionally.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vit D | 800IU/day |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2017-12-15
- Completion
- 2018-01-20
- First posted
- 2011-09-23
- Last updated
- 2023-03-06
Locations
13 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01439776. Inclusion in this directory is not an endorsement.